Skip to content

To Compare and See the effect of two species of ayurvedic herb sariva in the management of Mukhdushika (Acne Vulgaris)

A Clinical Study To Compare Shweta Sariva-Hemidesmus Indicus (Linn.) R. Br. And Krishna Sariva- Cryptolepis Buchanani Roem & Schult In The Management Of Mukhdushika (Acne Vulgaris). - NIL

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/07/070715
Enrollment
50
Registered
2024-07-16
Start date
Unknown
Completion date
Unknown
Last updated
2024-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L99- Other disorders of skin and subcutaneous tissue in diseases classified elsewhere

Interventions

None listed

Sponsors

Kajal Dabas
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Voluntary males/females with sign and symptoms of Mukhdushika . 2. Patients from age group of 15-40 years will be selected. 3. No treatment of acne in past 10 days. 4. All skin types (greasy, normal) except sensitive skin. 5. Accepting not to use products with the same end benefits during the entire study duration. 6. Having signed a Consent Form and will be once informed orally and in writing of all information concerning the study procedures and study objectives.

Exclusion criteria

Exclusion criteria: 1. Patients having dermatological or any other medical problem such as folliculitis and boils or history of allergic dermatitis. 2. Patients using any topical retinoid, topical and systemic steroids, throughout the duration of the study. 3. Patients who are known cases of immune-compromised disease, uncontrolled diabetes, any systemic illness which may interfere with study treatment and procedure. 4. Patients who are known cases of any malignancy. 5. Pregnant and lactating women and patients who are known cases of PCOD or any other gynaecological problems. 6. Any known hypersensitivity to any cosmetic and raw material. 7. Subject in an exclusion period or participating in another similar cosmetic or therapeutic trial

Design outcomes

Primary

MeasureTime frame
-Efficacy will be checked through the GAGS score and subjective criteria after treatment period of 30 days. Timepoint: GAGS Score reduced during 30 days of treatment period

Secondary

MeasureTime frame
Relapsing of the disease will be assessed in the follow up period that is 45th and 60th day of our trial. -Changes in affected area will also be assessed.Timepoint: Follow up at 45th & 60th day of trial

Countries

India

Contacts

Public ContactKAJAL DABAS

Institute for Ayurved Studies and Research

docarora26@gmail.com8901309502

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026